Details of the Drug Reposition

General Information of This Drug (ID: DMYKNME)

Drug Name
Ritlecitinib   DMYKNME
Synonyms
PF-06651600; CBRJPFGIXUFMTM-WDEREUQCSA-N; 1792180-81-4; UNII-2OYE00PC25; 2OYE00PC25; PF06651600; 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one; GTPL9559; SCHEMBL16764638; BCP24778; EX-A2613; ZINC526061581; example 5 [WO2015083028]; ACN-040697; compound 11 [PMID: 28139931]; HY-100754; CS-0020243; 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Alopecia areata DIS0XXBJ ED70.2 Approved [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Asthma DISW9QNS CA23 Phase 2 [2]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Crohn disease DIS2C5Q8 DD70 Phase 1 [3]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215830
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)